Scribble

Price Momentum

PFE is trading near the top of its 52-week range and above its 200-day simple moving average.
Price change

The price of PFE shares has increased $0.05 since the market last closed. This is a 0.20% rise.
Opened at $27.01.

The stock opened $0.15 higher than its previous close.

Key terms

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Market cap: $152.73B

A market capitalization between $10 billion and $200 billion places PFE in the large capitalization category.

Key terms

Smart score

Yesterday 12:33pm ET Pfizer Advances Early-Stage Cancer Candidate PF-07994525, Extending Its Oncology Pipeline by TipRanks Yesterday 10:50am ET Mixed options sentiment in Pfizer with shares down 1.23% by TipRanks Yesterday 2:36am ET Pfizer (PFE) Gets a Hold from Berenberg Bank by TipRanks Mar 11, 2026 3:10pm ET Mixed options sentiment in Pfizer with shares down 0.39% by TipRanks Mar 11, 2026 12:30pm ET Pfizer Advances Next-Gen Pneumococcal Vaccine With Completed Phase 2 Toddler Study by TipRanks Mar 11, 2026 7:06am ET Wells Fargo Sticks to Its Hold Rating for Pfizer (PFE) by TipRanks Mar 11, 2026 7:00am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kairos Pharma, Ltd. (KAPA), Pfizer (PFE) and Medtronic (MDT) by TipRanks Mar 10, 2026 12:50pm ET Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) by TipRanks Mar 10, 2026 6:57am ET Scotiabank Sticks to Their Buy Rating for Pfizer (PFE) by TipRanks Mar 10, 2026 6:51am ET BioNTech sees FY26 revenue EUR 2B-EUR 2.3B by TipRanks Mar 09, 2026 6:50am ET Pfizer reports ‘positive’ results from Phase 2 study of tilrekimig by TipRanks Mar 08, 2026 4:55pm ET Controversial Prasad leaving FDA, NYT reports by TipRanks Mar 07, 2026 10:02am ET Pfizer Stock Watch: New Drug Trials Aim to Reignite Growth by TipRanks Mar 06, 2026 12:11pm ET Midday Fly By: Rising oil prices, falling employment sink stocks by TipRanks Mar 06, 2026 11:32am ET Pfizer Adds New Early-Stage Heart Failure Candidate to Its China Pipeline by TipRanks Mar 06, 2026 6:38am ET Pfizer’s GLP-1 treatment for weight loss approved in China, Reuters says by TipRanks Mar 06, 2026 2:37am ET Pfizer’s Weight-Loss Drug Approved in China — Up Against Generic Rivals by TipRanks Mar 05, 2026 3:11pm ET Mixed options sentiment in Pfizer with shares down 0.39% by TipRanks Mar 05, 2026 9:00am ET Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX) by TipRanks Mar 04, 2026 8:48am ET ParaZero appoints Bat-Sheva Noy as VP, global sales by TipRanks Mar 04, 2026 7:50am ET Wells Fargo Sticks to Its Hold Rating for Pfizer (PFE) by TipRanks Mar 03, 2026 11:31am ET Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value by TipRanks Mar 02, 2026 2:55pm ET PPH, IHE, PJP: U.S. Pharmaceutical ETFs Offer Investors Innovation and Growth by TipRanks Mar 02, 2026 9:56am ET Netflix upgraded, Pinterest downgraded: Wall Street’s top analyst calls by TipRanks Mar 02, 2026 9:55am ET Positive Report for Pfizer (PFE) from Argus Research by TipRanks Mar 02, 2026 7:37am ET Argus upgrades Pfizer to Buy, citing GLP-1 pipeline, oncology programs by TipRanks Mar 02, 2026 7:30am ET Pfizer upgraded to Buy from Hold at Argus by TipRanks Mar 02, 2026 7:14am ET Apellis appoints Mikael Dolsten to board of directors by TipRanks Feb 28, 2026 10:02am ET Pfizer Ramps Up Obesity, mRNA Flu and Skin-Drug Bets by TipRanks Feb 27, 2026 11:41am ET Pfizer Quietly Advances New Obesity Shot With Fresh Phase 1 Study Update by TipRanks Feb 27, 2026 11:40am ET Pfizer Advances mRNA Flu Vaccine Pipeline With New Phase 2 Trial by TipRanks

1-year income & revenue

Total revenue: $62.58B (1Y), $17.56B (Q4)

Total Revenue held flat since last year and held flat since last quarter.
Net income: $7.77B (1Y), -$1.65B (Q4)

Net Income decreased 3.1% since last year and decreased 146.54% since last quarter.
Earnings per share: $1.36 (1Y), -$0.29 (Q4)

EPS decreased 3.63% since last year and increased 0.0% since last quarter.

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

How competitors are chosen

PFE's competitors are included in the Health Technology sector and Pharmaceuticals: Major group
Market cap: $152.73B

A market capitalization between $10 billion and $200 billion places PFE in the large capitalization category.